Customize your JAMA Network experience by selecting one or more topics from the list below.
Taiwan is a country of about 24 million people, 81 miles off the coast of mainland China. As of late April 2020, Taiwan had about 330 confirmed cases of coronavirus disease 2019 (COVID-19) and 6 deaths. By comparison, the US had about 1 million confirmed cases of COVID-19, and 60 000 deaths.
In this issue of JAMA Internal Medicine, there is a remarkable report from Taiwan on the use of contact tracing and virologic polymerase chain reaction testing to assess the transmission dynamics of COVID-19 in the country’s initial 100 confirmed cases.1 Among 2761 close contacts of the 100 cases, confirmed between January 15 and March 18, 2020, Cheng et al report that there were 22 paired-index secondary cases and an overall secondary clinical attack rate of 0.7% (95% CI, 0.4%-1.0%).1
The study has important messages for the control of COVID-19 throughout the world. First, people with COVID-19 were found to be most infectious to others before and within 5 days of symptom onset. Within 5 days of symptom onset, the attack rate was 1.0% (95% CI, 0.6%-1.5%). With exclusive presymptomatic exposures, the attack rate was 0.7% (95% CI, 0.2%-2.4%), and with exposures 6 days or more after symptom onset, there were 0 cases from 852 contacts (95% CI, 0%-0.4%).1
These findings underscore the pressing public health need for accurate and comprehensive contact tracing and testing. Testing only those people who are symptomatic will miss many infections and render contact tracing less effective. The finding that asymptomatic people and those with minimal or fewer symptoms early in infection are those most likely to transmit COVID-19 strongly argues for maintaining social distancing and having people wear face masks to reduce the potential for transmission. Solely isolating patients symptomatic with COVID-19 will fail to control transmission during the infected but asymptomatic stage.
Second, the study underscores the many things that Taiwan has done right in proactively and rapidly responding to COVID-19.2 It is impressive, even astounding, that Taiwan not only conducted robust contact tracing and testing on the first 100 confirmed cases, but also quickly and comprehensively reported the results, thus meaningfully advancing knowledge of the transmission dynamics of the virus.1 Unfortunately, widespread testing was not available in the US in February 2020, hampering the ability to identify people who were COVID-19 positive.
A first step for the US and other nations in “reopening” society is to have sufficient testing and contact tracing such that the outbreaks that will inevitably occur as social restrictions are removed can be successfully contained. Beyond this, even when “reopening,” social distancing throughout society and the wearing of face masks should be maintained to the maximum extent possible until there is a vaccine or effective treatment.
Published Online: May 1, 2020. doi:10.1001/jamainternmed.2020.2072
Corresponding Author: Robert Steinbrook, MD, JAMA Internal Medicine, Editorial Office, University of California, San Francisco, 505 Parnassus Ave, Ste M1180, PO Box 0124, San Francisco, CA 94143-0124 (email@example.com).
Conflict of Interest Disclosures: None reported.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Steinbrook R. Contact Tracing, Testing, and Control of COVID-19—Learning From Taiwan. JAMA Intern Med. 2020;180(9):1163–1164. doi:10.1001/jamainternmed.2020.2072
Coronavirus Resource Center